Arrowhead Pharmaceuticals, Inc.

LSE:0HI3 Stock Report

Market Cap: US$2.3b

Arrowhead Pharmaceuticals Management

Management criteria checks 3/4

Arrowhead Pharmaceuticals' CEO is Chris Anzalone, appointed in Dec 2007, has a tenure of 16.92 years. total yearly compensation is $9.92M, comprised of 9.1% salary and 90.9% bonuses, including company stock and options. directly owns 2.99% of the company’s shares, worth $68.88M. The average tenure of the management team and the board of directors is 6.4 years and 14 years respectively.

Key information

Chris Anzalone

Chief executive officer

US$9.9m

Total compensation

CEO salary percentage9.1%
CEO tenure16.9yrs
CEO ownership3.0%
Management average tenure6.4yrs
Board average tenure14yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Anzalone's remuneration changed compared to Arrowhead Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$539m

Mar 31 2024n/an/a

-US$471m

Dec 31 2023n/an/a

-US$297m

Sep 30 2023US$10mUS$903k

-US$205m

Jun 30 2023n/an/a

-US$181m

Mar 31 2023n/an/a

-US$150m

Dec 31 2022n/an/a

-US$155m

Sep 30 2022US$12mUS$863k

-US$176m

Jun 30 2022n/an/a

-US$154m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021n/an/a

-US$183m

Sep 30 2021US$25mUS$837k

-US$141m

Jun 30 2021n/an/a

-US$126m

Mar 31 2021n/an/a

-US$110m

Dec 31 2020n/an/a

-US$103m

Sep 30 2020US$14mUS$786k

-US$85m

Jun 30 2020n/an/a

-US$24m

Mar 31 2020n/an/a

US$10m

Dec 31 2019n/an/a

US$53m

Sep 30 2019US$2mUS$674k

US$68m

Jun 30 2019n/an/a

US$46m

Mar 31 2019n/an/a

US$10m

Dec 31 2018n/an/a

-US$29m

Sep 30 2018US$2mUS$643k

-US$54m

Compensation vs Market: Chris's total compensation ($USD9.92M) is above average for companies of similar size in the UK market ($USD2.13M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Anzalone (55 yo)

16.9yrs

Tenure

US$9,918,093

Compensation

Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Anzalone
CEO, President & Director16.9yrsUS$9.92m2.99%
$ 68.9m
Kenneth Myszkowski
Chief Financial Officer14.8yrsUS$3.12m0.19%
$ 4.4m
Patrick O'Brien
COO, General Counsel & Secretary9.9yrsUS$3.31m0.23%
$ 5.3m
James Hamilton
Chief of Discovery & Translational Medicineno dataUS$3.05m0.16%
$ 3.8m
Mark Davis
Founder and Founder & Director of Insert Therapeutics Inc & Calandono datano datano data
Vincent Anzalone
Head of Investor Relations & VPno datano datano data
Howard Lovy
Director of Communications19.3yrsno datano data
Bruce Given
Chief Medical Scientistless than a yearUS$16.34mno data
Mark Seefeld
Head of Toxicology & VPno datano datano data
Aaron Tan
Head of Tax2.8yrsno datano data
Andy Davis
SVP of Cardiovascular & Head of Metabolic Franchiseno datano datano data
Nadia Meshkova
VP & Treasurer2.8yrsno datano data

6.4yrs

Average Tenure

59yo

Average Age

Experienced Management: 0HI3's management team is seasoned and experienced (6.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Anzalone
CEO, President & Director16.9yrsUS$9.92m2.99%
$ 68.9m
Mark Davis
Founder and Founder & Director of Insert Therapeutics Inc & Calandono datano datano data
Douglass Given
Chairman of the Board14yrsUS$474.60k0.11%
$ 2.6m
Michael Perry
Independent Lead Director12.9yrsUS$459.60k0.074%
$ 1.7m
William Waddill
Independent Director6.8yrsUS$469.60k0.026%
$ 609.6k
Ching-Lung Lai
Member of Hepatitis B Clinical Advisory Boardno datano datano data
Robert Gish
Chairman of Hepatitis B Clinical Advisory Boardno datano datano data
Mauro Ferrari
Independent Director14.3yrsUS$459.60k0.037%
$ 848.9k
Jeffrey Teckman
Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Boardno datano datano data
Stephen Locarnini
Member of Hepatitis B Clinical Advisory Boardno datano datano data
Johnson Lau
Member of Hepatitis B Clinical Advisory Boardno datano datano data
Carlo Ferrari
Member of Hepatitis B Clinical Advisory Boardno datano datano data

14.0yrs

Average Tenure

65yo

Average Age

Experienced Board: 0HI3's board of directors are seasoned and experienced ( 14 years average tenure).